Detection of IDH1 and IDH2 mutations in denovo acute myeloid leukemia patients at National Cancer Institute, Cairo University /
Hend Abdelhady Nooh Mahmood
Detection of IDH1 and IDH2 mutations in denovo acute myeloid leukemia patients at National Cancer Institute, Cairo University / في حالات سرطان الدم الميلودي الحاد الحديثة التشخيص بالمعهد القومي للاورام - جامعة القاهرة Isocitrate Dehydrogenase (IDH 1,2) كشف الطفرة الجينيه لجيني Hend Abdelhady Nooh Mahmood ; Supervised Ragia H. Badawy , Yasser H. Elnahhas , Fatma A. Elrefaey - Cairo : Hend Abdelhady Nooh Mahmood , 2019 - 187 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
Introduction: AML is characterized by the uncontrolled clonal proliferation of poorly differentiated cells of myeloblasts. Isocitrate dehydrogenases (IDH1&2) are enzymes involved in multiple metabolic and epigenetic cellular processes. Mutations in IDH1 or IDH2 induce production of an oncometabolite, 2-hydroxyglutarate (R-2-HG) which leads to DNA hypermethylation, and abnormal differentiation. IDH mutations diversely affect prognosis of patients with AML based on the presence of other co-occurring genomic abnormalities. Aim of the work : The aim of this study was to assess the frequency of IDH1& IDH2 genes mutations in AML patients and evaluate their role in disease prognosis. Patients and Methods: We analyzed IDH mutations in 70 denovo AML patients (exon 4 for IDH1& exon 4 for IDH2) using High Resolution Melting (HRM) curve analysis
AML (Acute Myeloid Leukemia) IDH (Isociterate Dehydrogenase) Karyotype
Detection of IDH1 and IDH2 mutations in denovo acute myeloid leukemia patients at National Cancer Institute, Cairo University / في حالات سرطان الدم الميلودي الحاد الحديثة التشخيص بالمعهد القومي للاورام - جامعة القاهرة Isocitrate Dehydrogenase (IDH 1,2) كشف الطفرة الجينيه لجيني Hend Abdelhady Nooh Mahmood ; Supervised Ragia H. Badawy , Yasser H. Elnahhas , Fatma A. Elrefaey - Cairo : Hend Abdelhady Nooh Mahmood , 2019 - 187 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
Introduction: AML is characterized by the uncontrolled clonal proliferation of poorly differentiated cells of myeloblasts. Isocitrate dehydrogenases (IDH1&2) are enzymes involved in multiple metabolic and epigenetic cellular processes. Mutations in IDH1 or IDH2 induce production of an oncometabolite, 2-hydroxyglutarate (R-2-HG) which leads to DNA hypermethylation, and abnormal differentiation. IDH mutations diversely affect prognosis of patients with AML based on the presence of other co-occurring genomic abnormalities. Aim of the work : The aim of this study was to assess the frequency of IDH1& IDH2 genes mutations in AML patients and evaluate their role in disease prognosis. Patients and Methods: We analyzed IDH mutations in 70 denovo AML patients (exon 4 for IDH1& exon 4 for IDH2) using High Resolution Melting (HRM) curve analysis
AML (Acute Myeloid Leukemia) IDH (Isociterate Dehydrogenase) Karyotype